Actively Recruiting
Evaluating the Safety and Dose of AN8025 for Adults with Advanced or Metastatic Solid Tumors
Led by Adlai Nortye Biopharma Co., Ltd. · Updated on 2026-06-10
91
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating AN8025, a multifunctional antibody fusion protein, for the treatment of adults with advanced or metastatic solid tumors. This is a first-in-human, open-label, multi-center Phase 1 study designed to determine the safe and tolerable dose levels of AN8025 and to identify the maximum tolerated dose for future testing. The study will enroll adults aged 18 and older who have advanced solid tumors that have progressed after standard therapies or who cannot tolerate or refuse such treatments. Participants will receive AN8025 intravenously over 60 minutes on the first day of each 21-day treatment cycle. The study consists of two parts Part A focuses on dose escalation to find the appropriate dose, and Part B involves dose expansion in tumor-specific cohorts to assess pharmacokinetics and preliminary anti-tumor activity. Treatment continues for up to 24 months or until disease progression, unacceptable toxicity, withdrawal, or death. The study includes screening up to 35 days before dosing, followed by treatment cycles and a follow-up phase. During the study, participants will visit the clinic every 21 days for treatment and safety assessments, including blood tests to monitor drug levels and side effects. Follow-up involves an end-of-treatment visit, a 30-day safety check, and survival contacts every three months up to 6 to 12 months after treatment ends. Researchers will evaluate safety over 24 months and measure outcomes such as pharmacokinetics, objective response rate, disease control, duration of response, and progression-free survival.
CONDITIONS
Brief Title
An Initial Evaluation of AN8025 in Solid Tumors
Research Team
R
Regulatory Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here